慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

Continued strong growth in the gMG market was the primary driver of the outperformance and it was slightly complemented by the initial CIDP launch in the United States. The pipeline continues to ...

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term ...

Jason Eagle was enjoying his time in the U.S. Navy when, about a decade ago, he realized something was off. He started to experience numbness in his leg, lost sensation in his hands and developed ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only ...

在生物制药行业中，一些创新药物无疑能引起广泛关注，而再鼎医药有限公司的最新财报发布可以说为业内注入了一剂强心针。2024年第三季度，再鼎医药的产品收入净额达到1.018亿美元，较去年同期增长47%。这一成绩并非偶然，而是全公司持续努力、精密布局的结果。 卫伟迦（艾加莫德）作为公司重磅产品之一，正在成为治疗全身型重症肌无力（gMG）的革命性药物。今年1月，卫伟迦被纳入国家医保药品目录（NRDL），上 ...

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病 1 。CIDP患者会经历一系列的行动和感觉问题，包括从 ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating ...